ID   PC-9/ER/WR
AC   CVCL_DG28
DR   cancercelllines; CVCL_DG28
DR   Wikidata; Q54938488
RX   PubMed=26980747;
CC   Population: Chinese; Han and Japanese.
CC   Selected for resistance to: ChEBI; CHEBI_114785; Erlotinib.
CC   Selected for resistance to: ChEBI; CHEBI_61400; WZ4002 (N-(3-(5-chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)acrylamide).
CC   Sequence variation: Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_B260 ! PC-9
SX   Male
AG   45Y
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 19-12-24; Version: 15
//
RX   PubMed=26980747; DOI=10.18632/oncotarget.8013; PMCID=PMC5008340;
RA   Park, Ji Hyun
RA   Choi, Yun Jung
RA   Kim, Seon Ye
RA   Lee, Jung-Eun
RA   Sung, Ki Jung
RA   Park, Sojung
RA   Kim, Woo Sung
RA   Song, Joon Seon
RA   Choi, Chang-Min
RA   Sung, Young Hoon
RA   Rho, Jin Kyung
RA   Lee, Jae Cheol
RT   "Activation of the IGF1R pathway potentially mediates acquired
RT   resistance to mutant-selective 3rd-generation EGF receptor tyrosine
RT   kinase inhibitors in advanced non-small cell lung cancer.";
RL   Oncotarget 7:22005-22015(2016).
//